Drug Trial Radar · NCT02400476
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
Last checked: Nov 19, 2026Latest source record: May 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
563
Actual
Start
Feb 2015
Primary completion
Apr 22, 2021
Study completion Apr 22, 2021
Sponsor
- Lead sponsor
- Puma Biotechnology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 27, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Loperamide or other prophylactic measures.
Conditions
- Early Stage HER2+ Breast Cancer
Interventions
NeratinibDrug
LoperamideDrug
ColestipolDrug
2 g twice daily with or without food for one 28 day cycle
BudesonideDrug
9 mg extended release tablets once daily with or without food for 28 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients With Grade 3 or Higher Diarrhea, According to NCI CTCAE v4.0.Time frame: From first dose of investigational product through 28 days after last dose, up to 15.5 months.
Locations
58 sites in 7 countries. Site status is shown where the registry gives one.
Alabama Oncology
Birmingham, Alabama
Compassionate Care Research Group Inc.
Corona, California
St. Joseph Heritage Healthcare
Fullerton, California
Ronald Reagan UCLA Medical Center
Los Angeles, California
Emad Ibrahim, M.D., Inc.
Redlands, California
Torrance Memorial Physician Network Cancer Care Associates
Redondo Beach, California
Compassionate Care Research Group Inc.
Riverside, California
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California
The Oncology Institute of Hope and Innovation
Santa Ana, California
Cancer Center of Santa Barbara with Sansum Clinic
Santa Barbara, California
Central Coast Medical Oncology Corporation
Santa Maria, California
Memorial Healthcare System
Hollywood, Florida
Florida Cancer Research Institute, LLC
Plantation, Florida
Hematology-Oncology Associates of the Treasure Coast
Port Saint Lucie, Florida
Baptist Health Urgent Care Sawgrass
Sunrise, Florida
Cancer Treatment Centers of America
Newnan, Georgia
Decatur Memorial Hospital Cancer Care Specialists of Central Illinois
Decatur, Illinois
Ingalls Memorial Hospital
Harvey, Illinois
Norton Cancer Institute
Louisville, Kentucky
Central Maine Medical Center
Lewiston, Maine
University of Maryland, Greenebaum Comprehensive Cancer Center
Baltimore, Maryland
North Mississippi Medical Center Hematology and Oncology Services
Tupelo, Mississippi
Washington University School of Medicine
St Louis, Missouri
Great Plains Health (Callahan Cancer Center)
North Platte, Nebraska
Saint Barnabas Medical Center
Livingston, New Jersey
Jersey Shore University Medical Center
Neptune City, New Jersey
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
MD Anderson Cancer Center at Cooper
Voorhees Township, New Jersey
Clinical Research Alliance, Inc
Lake Success, New York
Good Samaritan Hospital Samaritan Pastega Regional Cancer Center
Corvallis, Oregon
Providence Portland Medical Center
Portland, Oregon
Magee-Womens Hospital of UPMC
Pittsburgh, Pennsylvania
Charleston Hematology Oncology Associates
Charleston, South Carolina
Saint Joseph / Candler SC Cancer Specialists
Hilton Head Island, South Carolina
Coastal Bend Cancer Center
Corpus Christi, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
Community Cancer Trials of Utah
Ogden, Utah
Utah Cancer Specialists
Salt Lake City, Utah
Inova Schar Cancer Institute
Fairfax, Virginia
Sydney Adventist Hospital
Wahroonga, New South Wales, Australia
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.